489 related articles for article (PubMed ID: 31604537)
1. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E; Wu RC; Bruno TC; Workman CJ; Vignali DAA
Semin Immunol; 2019 Apr; 42():101305. PubMed ID: 31604537
[TBL] [Abstract][Full Text] [Related]
2. LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP; Marciscano AE; Drake CG; Vignali DA
Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
[TBL] [Abstract][Full Text] [Related]
3. LAG3 (CD223) and autoimmunity: Emerging evidence.
Hu S; Liu X; Li T; Li Z; Hu F
J Autoimmun; 2020 Aug; 112():102504. PubMed ID: 32576412
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples.
Liu Q; Qi Y; Zhai J; Kong X; Wang X; Wang Z; Fang Y; Wang J
Front Immunol; 2021; 12():599207. PubMed ID: 34267742
[TBL] [Abstract][Full Text] [Related]
6. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
7. LAG3's Enigmatic Mechanism of Action.
Graydon CG; Mohideen S; Fowke KR
Front Immunol; 2020; 11():615317. PubMed ID: 33488626
[TBL] [Abstract][Full Text] [Related]
8. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
9. Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells.
Somasundaram A; Cillo AR; Lampenfeld C; Workman CJ; Kunning S; Oliveri L; Velez M; Joyce S; Calderon M; Dadey R; Rajasundaram D; Normolle DP; Watkins SC; Herman JG; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Vignali DAA
Cancer Immunol Res; 2022 Jul; 10(7):885-899. PubMed ID: 35587532
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
Andrews LP; Cillo AR; Karapetyan L; Kirkwood JM; Workman CJ; Vignali DAA
Clin Cancer Res; 2022 Dec; 28(23):5030-5039. PubMed ID: 35579997
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
Front Immunol; 2021; 12():785091. PubMed ID: 35111155
[TBL] [Abstract][Full Text] [Related]
14. Understanding the checkpoint blockade in lung cancer immunotherapy.
Dal Bello MG; Alama A; Coco S; Vanni I; Grossi F
Drug Discov Today; 2017 Aug; 22(8):1266-1273. PubMed ID: 28600190
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory receptors as targets for cancer immunotherapy.
Turnis ME; Andrews LP; Vignali DA
Eur J Immunol; 2015 Jul; 45(7):1892-905. PubMed ID: 26018646
[TBL] [Abstract][Full Text] [Related]
17. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
[TBL] [Abstract][Full Text] [Related]
18. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
[TBL] [Abstract][Full Text] [Related]
19. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
[TBL] [Abstract][Full Text] [Related]
20. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif.
Aigner-Radakovics K; De Sousa Linhares A; Salzer B; Lehner M; Izadi S; Castilho A; Pickl WF; Leitner J; Steinberger P
Sci Signal; 2023 Oct; 16(805):eadg2610. PubMed ID: 37788323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
